Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone With Better Mechanical Properties in Mice With Moderate-to-Severe Osteogenesis Imperfecta
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone With Better Mechanical Properties in Mice With Moderate-to-Severe Osteogenesis Imperfecta
"We have again demonstrated that, NP159, a surrogate murine antibody for NC605, reduces fracture incidence in both male and female OI mice. Given sexual dimorphism seen with OI, we noted improved bone quality in the treated male mice specifically," said Solomon Langermann, Ph.D., NextCure's chief scientific officer. "We continue to believe that NC605 has the potential to be a transformative agent for both female and male OI patients."BELTSVILLE, Md., Nov. 19, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the presentation of preclinical data demonstrating that treatment with NC605, a novel anti-Siglec-15 (S15) antibody, resulted in enhanced generation of quality bone with better mechanical properties, in an oral presentation at the Osteogenesis Imperfecta Federation Europe virtual Investigator Meeting on November 15th, 2024. These results demonstrate that NC605 is a highly effective treatment for Osteogenesis Imperfecta (OI), also known as brittle bone disease in a well-established model of disease.
馬里蘭州貝爾茨維爾，2024年11月19日（環球新聞社）—nextcure，Inc.（納斯達克：NXTC）一家臨床階段的生物製藥公司，致力於發現和開發治療癌症的新穎、一流和最佳藥物，今天宣佈，用NC605治療可以增強質量更好機械性能的骨骼的預臨床數據展示結果。這是通過在2024年11月15日歐洲骨生成不全聯盟虛擬調查員會議上口頭報告展示的。這些結果表明NC605是骨生成不全（OI），也被稱爲脆性骨病的高效治療方法，在已建立的疾病模型中。
OI is a rare disorder that results in high bone turnover, abnormal bone formation, bone fragility and recurrent fractures. There is no cure for OI. Current anti-resorptive treatments inhibit both bone loss and bone formation leading to an increase in bone density, but overall poor bone quality. In contrast, NC605 inhibits bone loss and enhances osteoblast recruitment, to produce new bone, resulting in the generation of quality bone with increased density.
成骨不全（OI）是一種罕見疾病，導致高骨代謝、異常骨形成、骨脆性和重複性骨折。尚無治療成骨不全的方法。目前的抗吸收治療可以抑制骨丟失和骨形成，從而導致骨密度增加，但整體骨質量較差。相反，NC605可以抑制骨丟失並增強成骨細胞招募，生成新骨，導致高質量骨生成，密度增加。
Fracture incidence and bone quality were assessed in male and female OI mice (oim) treated with 20 mg/kg of surrogate antibody NP159 (murine mAb parent to NC605) and compared to control groups. Key findings include:
我們評估了接受20 mg/kg替代抗體NP159（小鼠mAb母體NC605）治療的雄性和雌性OI小鼠（oim）的骨折發生率和骨質量，並與對照組進行對比。主要發現包括：
- In the treated mice, 90% of male oim and 80% of female oim, had no fractures post-sacrifice, compared to 85% and 55% in the control groups, respectively.
- For the treated oim population, both sexes showed:
- Increased trabecular and cortical tissue mineral density.
- Increased cortical bone mineral density.
- Collectively, all changes resulted in overall enhanced bone quality with better mechanical properties.
- In contrast, only the treated male oim population showed:
- Increased trabecular bone volume fraction, including an increase in the number of trabeculae and a decreased separation between trabeculae.
- Increased cortical thickness.
- Collectively, the changes resulted in an increase of max load and stiffness, measures of mechanical bone strength.
- 在接受治療的小鼠中，90%的雄性oim小鼠和80%的雌性oim小鼠在犧牲後無骨折，與對照組的85%和55%相比，具有顯著差異。
- 對於接受治療的oim群體，兩個性別均顯示：
- 骨小梁和皮質組織的礦物質密度增加。
- 皮質骨礦物質密度增加。
- 總的來說，所有變化導致整體骨質量增強，機械屬性更優。
- 相反，只有接受治療的男性oim人群顯示出：
- 骨小梁體積分數增加，包括骨小梁數量增加和骨小梁之間的間隔減少。
- 皮質厚度增加。
- 所有變化導致最大負荷和剛度增加，這是機械骨強度的衡量標準。
"We have again demonstrated that, NP159, a surrogate murine antibody for NC605, reduces fracture incidence in both male and female OI mice. Given sexual dimorphism seen with OI, we noted improved bone quality in the treated male mice specifically," said Solomon Langermann, Ph.D., NextCure's chief scientific officer. "We continue to believe that NC605 has the potential to be a transformative agent for both female and male OI patients."
「我們再次證明，NP159，一種NC605的替代小鼠抗體，在男性和女性OI小鼠中均降低了骨折發生率。考慮到OI中觀察到的性別二態性，我們特別注意到接受治療的雄性小鼠骨質量有所改善，」NextCure首席科學官所羅門·朗格曼（Dr. Solomon Langermann）博士說。「我們繼續相信，NC605有潛力成爲女性和男性OI患者的變革性藥物。」
The data were generated in collaboration with Dr. Cathleen Raggio, Hospital for Special Surgery, New York.
這些數據是與紐約特殊外科醫院的凱瑟琳·拉吉奧博士合作生成的。
About NextCure, Inc.
關於NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including antibody-drug conjugates, antibodies and proteins. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response.
NextCure是一家臨床階段的生物製藥公司，專注於推進治療癌症患者的創新藥物，這些患者對目前的療法沒有反應或疾病進展，通過使用抗體藥物偶聯物、抗體和蛋白質等差異化的作用機制。我們專注於推進利用我們在理解生物途徑和生物標誌物、細胞之間的相互作用（包括在腫瘤微環境中）及每種相互作用在生物學反應中所起的作用方面的核心優勢的治療方法。
Cautionary Statement Regarding Forward-Looking Statements
關於前瞻性聲明的警示聲明
Statements made in this press release that are not historical facts are forward-looking statements. Words such as "expects," "believes," "intends," "hope," "forward" and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, including that early clinical data may not be confirmed by later clinical results; risks that pre-clinical research may not be confirmed in clinical trials; risks related to marketing approval and commercialization; and NextCure's dependence on key personnel. More detailed information on these and additional factors that could affect NextCure's actual results are described in NextCure's filings with the Securities and Exchange Commission (the "SEC"), including NextCure's most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.
本新聞稿中的觀點而非歷史事實的表述爲前瞻性聲明。諸如 "預期"，"相信"，"打算"，"希望"，"前進" 等表達旨在識別前瞻性聲明。前瞻性聲明涉及重大風險和不確定性，可能導致實際結果與任何前瞻性聲明中預期的結果有實質性差異。此類風險和不確定性包括但不限於：我們有限的經營歷史和無任何已獲得商業銷售批准的產品；我們巨額的虧損歷史；我們需要獲取額外融資；與臨床發展相關的風險，包括早期臨床數據可能得不到後續臨床結果的證實；臨床前研究結果可能得不到臨床試驗的證實；與市場批准和商業化相關的風險；以及nextcure對關鍵員工的依賴。更詳細的關於這些以及可能影響nextcure實際結果的其他因素的信息，請參閱nextcure提交給美國證券交易委員會（「SEC」）的文件，包括nextcure最新的10-k表和隨後的10-Q表。您不應過於依賴任何前瞻性聲明。即使預期發生變化，nextcure也無義務更新任何前瞻性聲明。
Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com
投資者查詢
蒂莫西·邁耶博士
nextcure公司。
首席運營官
(240) 762-6486
IR@nextcure.com
譯文內容由第三人軟體翻譯。
